AstraZeneca (AZN) Receives “Hold” Rating from Shore Capital

Share on StockTwits

Shore Capital reiterated their hold rating on shares of AstraZeneca (LON:AZN) in a report published on Tuesday.

AZN has been the topic of a number of other research reports. Deutsche Bank lowered their price objective on shares of AstraZeneca from GBX 6,000 ($78.40) to GBX 5,700 ($74.48) and set a buy rating on the stock in a research note on Friday, July 20th. BNP Paribas set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the company a buy rating in a research note on Tuesday, September 11th. JPMorgan Chase & Co. set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the company a buy rating in a research note on Tuesday, September 25th. Barclays set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the company a buy rating in a research note on Friday, July 27th. Finally, Jefferies Financial Group set a GBX 6,200 ($81.01) price objective on shares of AstraZeneca and gave the company a neutral rating in a research note on Thursday, August 16th. Two analysts have rated the stock with a sell rating, eight have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Hold and an average target price of GBX 5,831.89 ($76.20).

LON AZN opened at GBX 6,172 ($80.65) on Tuesday. AstraZeneca has a 12 month low of GBX 4,260 ($55.66) and a 12 month high of GBX 5,520 ($72.13).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: Leveraged Buyout (LBO)

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.